BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19686692)

  • 1. Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus.
    Biesova Z; Miller MA; Schneerson R; Shiloach J; Green KY; Robbins JB; Keith JM
    Vaccine; 2009 Oct; 27(44):6234-8. PubMed ID: 19686692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
    Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
    Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prime-Boost Vaccination With a Novel Hemagglutinin Protein Produced in Bacteria Induces Neutralizing Antibody Responses Against H5-Subtype Influenza Viruses in Commercial Chickens.
    Sączyńska V; Romanik-Chruścielewska A; Florys K; Cecuda-Adamczewska V; Łukasiewicz N; Sokołowska I; Kęsik-Brodacka M; Płucienniczak G
    Front Immunol; 2019; 10():2006. PubMed ID: 31552018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge.
    Wang SH; Smith D; Cao Z; Chen J; Acosta H; Chichester JA; Yusibov V; Streatfield SJ; Fattom A; Baker JR
    Vaccine; 2019 Mar; 37(12):1591-1600. PubMed ID: 30795941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purification and immunogenicity of hemagglutinin from highly pathogenic avian influenza virus H5N1 expressed in Nicotiana benthamiana.
    Pua TL; Chan XY; Loh HS; Omar AR; Yusibov V; Musiychuk K; Hall AC; Coffin MV; Shoji Y; Chichester JA; Bi H; Streatfield SJ
    Hum Vaccin Immunother; 2017 Feb; 13(2):306-313. PubMed ID: 27929750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge.
    Major D; Chichester JA; Pathirana RD; Guilfoyle K; Shoji Y; Guzman CA; Yusibov V; Cox RJ
    Hum Vaccin Immunother; 2015; 11(5):1235-43. PubMed ID: 25714901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection.
    Asahi-Ozaki Y; Itamura S; Ichinohe T; Strong P; Tamura S; Takahashi H; Sawa H; Moriyama M; Tashiro M; Sata T; Kurata T; Hasegawa H
    Microbes Infect; 2006 Oct; 8(12-13):2706-14. PubMed ID: 16968669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
    Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
    J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
    Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
    Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insect cell-expressed hemagglutinin with CpG oligodeoxynucleotides plus alum as an adjuvant is a potential pandemic influenza vaccine candidate.
    Gong M; Zhou J; Yang C; Deng Y; Zhao G; Zhang Y; Wang Y; Zhou Y; Tan W; Xu H
    Vaccine; 2012 Dec; 30(52):7498-505. PubMed ID: 23116697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice.
    Mooney AJ; Li Z; Gabbard JD; He B; Tompkins SM
    J Virol; 2013 Jan; 87(1):363-71. PubMed ID: 23077318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response.
    Lee JS; Chowdhury MY; Moon HJ; Choi YK; Talactac MR; Kim JH; Park ME; Son HY; Shin KS; Kim CJ
    J Virol Methods; 2013 Dec; 194(1-2):280-8. PubMed ID: 24004822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.
    Isakova-Sivak I; Chen LM; Bourgeois M; Matsuoka Y; Voeten JT; Heldens JG; van den Bosch H; Klimov A; Rudenko L; Cox NJ; Donis RO
    Clin Vaccine Immunol; 2014 May; 21(5):722-31. PubMed ID: 24648485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
    Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nanoemulsion-adjuvanted intranasal H5N1 influenza vaccine protects ferrets against homologous and heterologous H5N1 lethal challenge.
    Smith D; Streatfield SJ; Acosta H; Ganesan S; Fattom A
    Vaccine; 2019 Sep; 37(42):6162-6170. PubMed ID: 31495593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prime/boost vaccination with HA DNA and Pichia-produced HA protein elicits a strong humoral response in chickens against H5N1.
    Stachyra A; Pietrzak M; Macioła A; Protasiuk A; Olszewska M; Śmietanka K; Minta Z; Góra-Sochacka A; Kopera E; Sirko A
    Virus Res; 2017 Mar; 232():41-47. PubMed ID: 28159612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.
    Khurana S; Verma S; Verma N; Crevar CJ; Carter DM; Manischewitz J; King LR; Ross TM; Golding H
    J Virol; 2011 Feb; 85(3):1246-56. PubMed ID: 21084473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monovalent H5 vaccine based on epitope-chimeric HA provides broad cross-clade protection against variant H5N1 viruses in mice.
    He F; Prabakaran M; Rajesh Kumar S; Tan Y; Kwang J
    Antiviral Res; 2014 May; 105():143-51. PubMed ID: 24637255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.